Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gazzah, A. [1 ]
Lee, J. S. [2 ]
Wang, E. [2 ]
Ternes, N. [3 ]
Wang, H. [2 ]
Boitier, E. [3 ]
Lartigau, A. [3 ]
Chadjaa, M. [3 ]
Dib, C. [3 ]
Muzard, G. [3 ]
Valence, S. [3 ]
Remaury, A. [3 ]
Palu, C. C. [4 ]
Bauchet, A-L. [3 ]
机构：
[1] Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71P
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [31] Phase II study of dasatinib in patients with advanced non-small cell lung cancer
    Johnson, F. M.
    Bekele, B. N.
    Feng, L.
    Wistuba, I. I.
    Tang, X.
    Tran, H. T.
    Erasmus, J. J.
    Hwang, L.
    Takebe, N.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] BIOMARKER PATTERN IN NEVER SMOKER PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Santos, Edgardo S.
    Ochoa, Roberto E.
    Bisneto, Jose Villasboas
    Gomez, Jorge E.
    Danenberg, Kathleen
    Raez, Luis E.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1111 - S1112
  • [33] Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study
    Steward, WP
    Dunlop, DJ
    Cameron, C
    Talbot, DC
    Kleisbauer, JL
    Thomas, P
    Guerin, JC
    Perol, M
    Sanson, C
    Dabouis, G
    Lacroix, H
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1081 - 1081
  • [34] PHASE I/II STUDY OF S-1 PLUS CARBOPLATIN (CBDCA) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Tamura, K.
    Okamoto, I.
    Ozaki, T.
    Kashii, T.
    Takeda, K.
    Kobayashi, M.
    Matsui, K.
    Shibata, T.
    Nakagawa, K.
    Fukuoka, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 108 - 108
  • [35] Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
    Hirata, T
    Kawashita, F
    Ogawa, E
    Masago, K
    Kato, M
    Takada, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 676S - 676S
  • [36] Carboplatin and vinorelbine in advanced non-small cell lung cancer: A phase I/II study
    Masters, G
    ONCOLOGIST, 2001, 6 : 12 - 15
  • [37] Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer
    Ogawara, Daiki
    Nakamura, Yoichi
    Fukuda, Minoru
    Nakatomi, Katsumi
    Yamaguchi, Hiroyuki
    Motoshima, Kohei
    Mizoguchi, Kosuke
    Nakano, Hirofumi
    Takemoto, Shinnosuke
    Gyotoku, Hiroshi
    Nagashima, Seiji
    Kohno, Shigeru
    CHEMOTHERAPY, 2014, 60 (03) : 180 - 184
  • [38] A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer
    Hotta, K
    Sekine, I
    Tamura, T
    Sawada, M
    Watanabe, H
    Kusaba, H
    Akiyama, Y
    Inoue, A
    Shimoyama, T
    Nokihara, H
    Ueda, Y
    Yamamoto, N
    Kunitoh, H
    Ohe, Y
    Kodama, T
    Saijo, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (12) : 596 - 600
  • [39] Evaluation of combined biomarker in response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramdani, H. O.
    Shatz, S.
    Falk, M.
    Heukamp, L. C.
    Tiemann, M.
    Wesseler, C.
    Schuuring, E.
    Groen, H. J.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 153 - 153
  • [40] Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.
    Johnson, Melissa Lynne
    Chadjaa, Mustapha
    Yoruk, Semra
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345